These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy. Lopes JE, Fisher JL, Flick HL, Wang C, Sun L, Ernstoff MS, Alvarez JC, Losey HC. J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32317293 [Abstract] [Full Text] [Related]
25. Tumor conditions induce bone marrow expansion of granulocytic, but not monocytic, immunosuppressive leukocytes with increased CXCR2 expression in mice. Bian Z, Shi L, Venkataramani M, Abdelaal AM, Culpepper C, Kidder K, Liang H, Zen K, Liu Y. Eur J Immunol; 2018 Mar; 48(3):532-542. PubMed ID: 29120053 [Abstract] [Full Text] [Related]
26. Treatment with a fusion protein of the extracellular domains of NKG2D to IL-15 retards colon cancer growth in mice. Xia Y, Chen B, Shao X, Xiao W, Qian L, Ding Y, Ji M, Gong W. J Immunother; 2014 Jun; 37(5):257-66. PubMed ID: 24810637 [Abstract] [Full Text] [Related]
29. Deciphering the Crosstalk Between Myeloid-Derived Suppressor Cells and Regulatory T Cells in Pancreatic Ductal Adenocarcinoma. Siret C, Collignon A, Silvy F, Robert S, Cheyrol T, André P, Rigot V, Iovanna J, van de Pavert S, Lombardo D, Mas E, Martirosyan A. Front Immunol; 2019 Jun; 10():3070. PubMed ID: 32038621 [Abstract] [Full Text] [Related]
32. FcγRIIB potentiates differentiation of myeloid-derived suppressor cells to mediate tumor immunoescape. Wu L, Xu Y, Zhao H, Zhou Y, Chen Y, Yang S, Lei J, Zhang J, Wang J, Wu Y, Li Y. Theranostics; 2022 Jun; 12(2):842-858. PubMed ID: 34976216 [Abstract] [Full Text] [Related]
36. The bispecific immunoligand ULBP2-aCEA redirects natural killer cells to tumor cells and reveals potent anti-tumor activity against colon carcinoma. Rothe A, Jachimowicz RD, Borchmann S, Madlener M, Keßler J, Reiners KS, Sauer M, Hansen HP, Ullrich RT, Chatterjee S, Borchmann P, Yazaki P, Koslowsky TC, Engert A, Heukamp LC, Hallek M, von Strandmann EP. Int J Cancer; 2014 Jun 15; 134(12):2829-40. PubMed ID: 24242212 [Abstract] [Full Text] [Related]
37. Interleukin-18 synergism with interleukin-2 in cytotoxicity and NKG2D expression of human natural killer cells. Qi YY, Lu C, Ju Y, Wang ZE, Li YT, Shen YJ, Lu ZM. Asian Pac J Cancer Prev; 2014 Jun 15; 15(18):7857-61. PubMed ID: 25292077 [Abstract] [Full Text] [Related]
38. Fc-Optimized Anti-CCR8 Antibody Depletes Regulatory T Cells in Human Tumor Models. Campbell JR, McDonald BR, Mesko PB, Siemers NO, Singh PB, Selby M, Sproul TW, Korman AJ, Vlach LM, Houser J, Sambanthamoorthy S, Lu K, Hatcher SV, Lohre J, Jain R, Lan RY. Cancer Res; 2021 Jun 01; 81(11):2983-2994. PubMed ID: 33757978 [Abstract] [Full Text] [Related]
39. Bispecific NKG2D-CD3 and NKG2D-CD16 fusion proteins for induction of NK and T cell reactivity against acute myeloid leukemia. Märklin M, Hagelstein I, Koerner SP, Rothfelder K, Pfluegler MS, Schumacher A, Grosse-Hovest L, Jung G, Salih HR. J Immunother Cancer; 2019 May 29; 7(1):143. PubMed ID: 31142382 [Abstract] [Full Text] [Related]